IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#748
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$1.6B
Jack C. Bendheim
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Dates updated upon official exchange announcement.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = PAHC ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$PAHC PHIBRO ANIMAL HEALTH CORP | 60 | 65 | 67 | 76 | 27.4x | 17.2x | 23.5% | 5.5% | 32.9% | 11.4% | 5.4% | 43.6% | 1.2% | 188.0x | $1.6B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
PHIBRO ANIMAL HEALTH CORP (PAHC) receives a "Hold" rating with a composite score of 59.5/100. It ranks #748 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Trading at a discount to fundamentals — favorable entry valuation
High profitability & efficiency — strong quality floor supports entry
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for PAHC.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 65 | 72 | -7DRAG |
| MOMENTUM | 76 | 81 | -5NEUTRAL |
| VALUATION | 67 | 65 | +2NEUTRAL |
| INVESTMENT | 22 | 5 | +17ALPHA |
| STABILITY | 53 | 49 | +4NEUTRAL |
| SHORT INT | 39 | 34 | +5NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy 23.5% (sector -1.9%)
GM 33% vs sector 44%, OM 11% vs sector 3%
Capital turnover N/A
Rev growth 44%, 11yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate PHIBRO ANIMAL HEALTH CORP (PAHC) as a Hold with a composite score of 59.5/100 at a current price of $51.44. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
PHIBRO ANIMAL HEALTH CORP holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 59.5/100 places it at rank #748 in our full universe.
The near-term outlook is constructive, with revenue growing at 44% and momentum in the 76th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
Narrow
Medium
Standard
Undervalued
Returns on equity of 23.5% exceed cost of capital.
Value factor score of 67 suggests attractive pricing.
Positive momentum indicates institutional accumulation.
Leverage of 188% D/E amplifies downside risk.
Vulnerability to macroeconomic shocks and interest rate volatility.
PHIBRO ANIMAL HEALTH CORP represents a hold based on multi-factor quantitative performance.
Our model assigns PHIBRO ANIMAL HEALTH CORP a Hold rating, with a composite score of 59.5/100 and 3 out of 5 stars. Ranked #748 of 7,333 stocks, PAHC presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
PAHC earns a quality score of 65/100, indicating above-average business quality. The company reports a return on equity of 23.5% (sector avg: -1.9%), gross margins of 32.9% (sector avg: 44.1%), net margins of 5.4% (sector avg: 1.0%). Companies in this tier generally demonstrate consistent profitability and efficient capital deployment, though they may face some competitive pressure.
PAHC's value score of 67/100 indicates the stock is fairly valued based on its current fundamentals. Key valuation metrics include a P/E ratio of 27.42x, an EV/EBITDA of 17.21x, a P/B ratio of 6.44x. At this level, neither a clear bargain nor overpriced, the stock's attractiveness depends more on forward growth expectations and qualitative factors.
PHIBRO ANIMAL HEALTH CORP's investment score of 22/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 43.6% vs. a sector average of 6.7% and a return on assets of 5.5% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
PAHC shows strong momentum characteristics with a score of 76/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at 43.6% year-over-year, while a beta of 1.03 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
With a stability score of 53/100, PAHC exhibits average financial resilience. Key stability metrics include a beta of 1.03 and a debt-to-equity ratio of 188.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
PHIBRO ANIMAL HEALTH CORP's short interest score of 39/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 188.00x), small-cap liquidity risk. At $1.6B (small-cap), PAHC carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
PAHC offers a modest dividend yield of 1.2%. While the income contribution is relatively small, even a small dividend signals management's commitment to shareholder returns and can serve as a signal of financial discipline.
PHIBRO ANIMAL HEALTH CORP is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #748 of 7,333 overall (90th percentile). Key comparisons include ROE of 23.5% exceeding the -1.9% sector median and operating margins of 11.4% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While PAHC currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Momentum (76) vs Investment (22) — closing this gap could shift the rating.
EV/EBITDA 50% ABOVE SECTOR MEDIAN
ROE 1336% BELOW SECTOR MEDIAN
Gross Margin 25% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Jack Bendheim, President and CEO of Phibro Animal Health Corporation, sold 72,198 shares indirectly for approximately $3.74 million between February 10-11, 2026, under a pre-existing Rule 10b5-1 trading plan. The sale occurred following strong Q2 2026 earnings with year-over-year growth in revenue, net income, and EPS. The company's medicated feed additive portfolio has grown faster than expected, particularly following its late 2024 acquisition of over 37 product lines.
Phibro Animal Health (NasdaqGM:PAHC) reported robust quarterly results, with strong growth in its Medicated Feed Additive business. Shortly after the earnings release, the CEO executed significant open market sales of company shares. The timing and size of the insider sale have drawn attention because they follow a period of rapid business expansion following acquisitions. For investors watching Phibro Animal Health, the backdrop is a stock that closed at $51.52 and has delivered a 32.1%...
In recent days, Phibro Animal Health reported stronger year-over-year Q2 fiscal 2026 results and a faster-than-expected expansion of its Medicated Feed Additive portfolio, while CEO Jack Bendheim sold 72,198 shares in multiple open-market transactions. The combination of accelerating portfolio growth following late 2024 acquisitions, analyst recognition of improved margins, and fresh investor outreach at a sector summit is reshaping how the company’s execution and future prospects are being...
Phibro Animal Health reported strong Q4 FY2025 earnings, with 39% revenue growth driven by the Zoetis medicated feed additive acquisition. Despite robust sales and adjusted EBITDA, gross margins declined due to higher distribution costs and product mix challenges.
Top-ranked stocks Revolve Group (RVLV), Phibro Animal Health (PAHC), Silicon Motion Technology (SIMO) and IPG Photonics (IPGP) are likely to beat on the bottom line in their upcoming releases.